Mycovia Pharmaceuticals

Durham, United States Founded: 2018 • Age: 8 yrs
Small molecule therapeutics are developed for recurrent vulvovaginal candidiasis treatment.

About Mycovia Pharmaceuticals

Mycovia Pharmaceuticals is a company based in Durham (United States) founded in 2018.. Mycovia Pharmaceuticals offers products and services including VIVJOA. Mycovia Pharmaceuticals operates in a competitive market with competitors including Scynexis, F2g, Amplyx Pharmaceuticals, Biosergen and Elion Therapeutics, among others.

  • Headquarter Durham, United States
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
    $710 K (USD), Grant

    Jun 20, 2018

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Mycovia Pharmaceuticals

Mycovia Pharmaceuticals offers a comprehensive portfolio of products and services, including VIVJOA. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Capsules used for treating fungal infections in patients.

People of Mycovia Pharmaceuticals
Headcount 10-50
Employee Profiles 11
Employee Profiles
People
Shawana Taylor M.d.
Senior Medical Science Liaison
People
Rachel Gee
VP, Project Management and Regulatory Affairs
People
Stephen Brand
Chief Development Officer
People
Patrick Jordan
CEO

Unlock access to complete

Funding Insights of Mycovia Pharmaceuticals

  • Total Funding
  • Total Rounds 1
  • Last Round Grant — $710,000
  • First Round

    (20 Jun 2018)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2018 Amount Grant - Mycovia Pharmaceuticals Valuation

investors

HHS
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Mycovia Pharmaceuticals

Mycovia Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Public health and human services are overseen by HHS.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Mycovia Pharmaceuticals

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Mycovia Pharmaceuticals

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Mycovia Pharmaceuticals Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Mycovia Pharmaceuticals

Mycovia Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Scynexis, F2g, Amplyx Pharmaceuticals, Biosergen and Elion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developing glucan synthase inhibitors for the treatment of fungal infections.
domain founded_year HQ Location
Drugs for systemic fungal diseases are discovered and developed.
domain founded_year HQ Location
Broad-spectrum fungal enzyme inhibitors are developed by clinical-stage biopharma.
domain founded_year HQ Location
Anti-fungal therapeutics are developed against invasive fungal diseases.
domain founded_year HQ Location
Therapeutics for invasive fungal infections are developed by Elion Therapeutics.
domain founded_year HQ Location
Therapies for chronic fungal infections are developed using metalloenzyme inhibitors.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Mycovia Pharmaceuticals

When was Mycovia Pharmaceuticals founded?

Mycovia Pharmaceuticals was founded in 2018.

Where is Mycovia Pharmaceuticals located?

Mycovia Pharmaceuticals is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.

What does Mycovia Pharmaceuticals do?

Founded in 2018 and based in Durham, United States, Mycovia Pharmaceuticals operates in the biopharmaceutical sector. Small molecule-based therapeutics are developed by the company to address recurrent vulvovaginal candidiasis in women. The lead candidate, VT-1161, targets fungal cytochrome P450 sterol 14α-demethylase and has advanced through Phase 2b clinical trials. Focus remains on innovative antifungal treatments within this specialized field.

Who are the top competitors of Mycovia Pharmaceuticals?

Mycovia Pharmaceuticals's top competitors include Scynexis, F2g and Amplyx Pharmaceuticals.

What products or services does Mycovia Pharmaceuticals offer?

Mycovia Pharmaceuticals offers VIVJOA.

Who are Mycovia Pharmaceuticals's investors?

Mycovia Pharmaceuticals has 1 investor. Key investors include HHS.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available